studies

mML - L1 - BRAF wild, immune chekpoint inhibitors vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 066, 2015 0.42 [0.25; 0.72] CheckMate 066 DUPLICATE, 2015 0.36 [0.24; 0.55] IMspire-170, 2020 1.06 [0.69; 1.62] 0.55[0.27; 1.10]CheckMate 066, 2015, CheckMate 066 DUPLICATE, 2015, IMspire-170, 2020386%1,282lownot evaluable deaths (OS) (extension)detailed resultsCheckMate 066, 2015 0.46 [0.36; 0.59] 0.46[0.36; 0.59]CheckMate 066, 201510%418NAnot evaluable PFS (extension)detailed resultsCheckMate 066, 2015 0.42 [0.33; 0.53] 0.42[0.33; 0.53]CheckMate 066, 201510%418NAnot evaluable progression or deaths (PFS)detailed resultsCheckMate 066, 2015 0.43 [0.34; 0.55] CheckMate 066 DUPLICATE, 2015 0.43 [0.34; 0.55] CheckMate 069 (BRAF wild type), 2015 0.40 [0.23; 0.69] IMspire-170, 2020 1.15 [0.88; 1.50] 0.55[0.32; 0.93]CheckMate 066, 2015, CheckMate 066 DUPLICATE, 2015, CheckMate 069 (BRAF wild type), 2015, IMspire-170, 2020492%1,391lownot evaluable DCRdetailed resultsIMspire-170, 2020 0.91 [0.63; 1.32] 0.91[0.63; 1.32]IMspire-170, 202010%446NAnot evaluable DOR (extension)detailed resultsCheckMate 066, 2015 3.45 [1.46; 8.18] 3.45[1.46; 8.18]CheckMate 066, 201510%120NAnot evaluable objective responses (ORR)detailed resultsCheckMate 066, 2015 4.06 [2.52; 6.54] CheckMate 066 DUPLICATE, 2015 4.06 [2.52; 6.54] CheckMate 069 (BRAF wild type), 2015 12.96 [3.47; 48.38] IMspire-170, 2020 0.77 [0.50; 1.17] 3.25[1.13; 9.33]CheckMate 066, 2015, CheckMate 066 DUPLICATE, 2015, CheckMate 069 (BRAF wild type), 2015, IMspire-170, 2020493%1,391lownot evaluable objective responses (ORR) (extension)detailed resultsCheckMate 066, 2015 4.50 [2.79; 7.25] CheckMate 069 (BRAF wild type), 2015 13.00 [3.48; 48.60] 6.35[2.40; 16.83]CheckMate 066, 2015, CheckMate 069 (BRAF wild type), 2015255%527lownot evaluable AE (any grade)detailed resultsCheckMate 066, 2015 0.78 [0.34; 1.76] IMspire-170, 2020 14.27 [3.34; 61.03] 3.12[0.18; 53.89]CheckMate 066, 2015, IMspire-170, 2020291%847lownot evaluable AE (grade 3-4)detailed resultsCheckMate 066, 2015 0.84 [0.56; 1.25] IMspire-170, 2020 4.03 [2.70; 6.00] 1.84[0.39; 8.56]CheckMate 066, 2015, IMspire-170, 2020297%847moderatenot evaluable AE leading to death (grade 5)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] IMspire-170, 2020 1.39 [0.43; 4.44] 1.35[0.44; 4.12]CheckMate 066, 2015, IMspire-170, 202020%847moderatenot evaluable AE leading to treatment discontinuation (any grade)detailed resultsCheckMate 066, 2015 0.55 [0.28; 1.10] 0.55[0.28; 1.10]CheckMate 066, 201510%411NAnot evaluable AE leading to treatment discontinuation (grade 3-4)detailed resultsCheckMate 066, 2015 0.61 [0.29; 1.28] 0.61[0.29; 1.28]CheckMate 066, 201510%411NAnot evaluable SAE (any grade)detailed resultsCheckMate 066, 2015 0.73 [0.49; 1.10] 0.73[0.49; 1.10]CheckMate 066, 201510%411NAnot evaluable SAE (grade 3-4)detailed resultsCheckMate 066, 2015 0.74 [0.47; 1.17] 0.74[0.47; 1.17]CheckMate 066, 201510%411NAnot evaluable STRAE (any grade)detailed resultsCheckMate 066, 2015 1.06 [0.54; 2.07] 1.06[0.54; 2.07]CheckMate 066, 201510%411NAnot evaluable STRAE (grade 3-4)detailed resultsCheckMate 066, 2015 0.99 [0.44; 2.27] 0.99[0.44; 2.27]CheckMate 066, 201510%411NAnot evaluable TRAE (any grade)detailed resultsCheckMate 066, 2015 0.93 [0.60; 1.46] 0.93[0.60; 1.46]CheckMate 066, 201510%411NAnot evaluable TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 0.62 [0.35; 1.08] 0.62[0.35; 1.08]CheckMate 066, 201510%411NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 069 (BRAF wild type), 2015 3.39 [1.40; 8.19] 3.39[1.40; 8.19]CheckMate 069 (BRAF wild type), 201510%108NAnot evaluable Abdominal pain TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 066, 201510%411NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 066, 201510%411NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 066, 201510%411NAnot evaluable Arthralgia TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 066, 201510%411NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 0.50 [0.02; 14.88] 0.50[0.02; 14.88]CheckMate 066, 201510%411NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 066, 201510%411NAnot evaluable Cough TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 066, 201510%411NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 066, 201510%411NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 2.00 [0.18; 22.23] 2.00[0.18; 22.23]CheckMate 066, 201510%411NAnot evaluable Dry skin TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 066, 201510%411NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 0.25 [0.01; 5.51] 0.25[0.01; 5.51]CheckMate 066, 201510%411NAnot evaluable Headache TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 066, 201510%411NAnot evaluable Hypersensitivity TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 066, 201510%411NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 2.00 [0.07; 59.80] 2.00[0.07; 59.80]CheckMate 066, 201510%411NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 066, 201510%411NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.06; 16.02] 1.00[0.06; 16.02]CheckMate 066, 201510%411NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 2.00 [0.18; 22.23] 2.00[0.18; 22.23]CheckMate 066, 201510%411NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 066, 201510%411NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 0.12 [0.01; 2.33] 0.12[0.01; 2.33]CheckMate 066, 201510%411NAnot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 2.00 [0.07; 59.80] 2.00[0.07; 59.80]CheckMate 066, 201510%411NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 066, 201510%411NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 066, 201510%411NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 0.05 [0.00; 0.92] 0.05[0.00; 0.92]CheckMate 066, 201510%411NAnot evaluable Pancytopenia TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 0.16 [0.01; 3.29] 0.16[0.01; 3.29]CheckMate 066, 201510%411NAnot evaluable Paraesthesia TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 066, 201510%411NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 2.00 [0.07; 59.80] 2.00[0.07; 59.80]CheckMate 066, 201510%411NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 0.50 [0.02; 14.88] 0.50[0.02; 14.88]CheckMate 066, 201510%411NAnot evaluable Rash TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 2.00 [0.07; 59.80] 2.00[0.07; 59.80]CheckMate 066, 201510%411NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 0.05 [0.00; 0.82] 0.05[0.00; 0.82]CheckMate 066, 201510%411NAnot evaluable Vitiligo TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.02; 50.40] 1.00[0.02; 50.40]CheckMate 066, 201510%411NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsCheckMate 066, 2015 1.00 [0.06; 16.02] 1.00[0.06; 16.02]CheckMate 066, 201510%411NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsIMspire-170, 2020 0.98 [0.14; 7.03] 0.98[0.14; 7.03]IMspire-170, 202010%436NAnot evaluable Anaemia AE (grade 3-4)detailed resultsIMspire-170, 2020 1.74 [0.50; 6.04] 1.74[0.50; 6.04]IMspire-170, 202010%436NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsIMspire-170, 2020 0.98 [0.02; 49.71] 0.98[0.02; 49.71]IMspire-170, 202010%436NAnot evaluable Asthenia AE (grade 3-4)detailed resultsIMspire-170, 2020 1.74 [0.50; 6.04] 1.74[0.50; 6.04]IMspire-170, 202010%436NAnot evaluable Constipation AE (grade 3-4)detailed resultsIMspire-170, 2020 0.98 [0.02; 49.71] 0.98[0.02; 49.71]IMspire-170, 202010%436NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMspire-170, 2020 1.97 [0.07; 58.97] 1.97[0.07; 58.97]IMspire-170, 202010%436NAnot evaluable Dermatitis acneiform AE (grade 3-4)detailed resultsOut of scaleIMspire-170, 2020 22.68 [1.32; 388.47] 22.68[1.32; 388.47]IMspire-170, 202010%436NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMspire-170, 2020 4.44 [1.47; 13.42] 4.44[1.47; 13.42]IMspire-170, 202010%436NAnot evaluable Fatigue AE (grade 3-4)detailed resultsIMspire-170, 2020 1.65 [0.39; 7.00] 1.65[0.39; 7.00]IMspire-170, 202010%436NAnot evaluable Headache AE (grade 3-4)detailed resultsIMspire-170, 2020 1.97 [0.07; 58.97] 1.97[0.07; 58.97]IMspire-170, 202010%436NAnot evaluable Hypertension AE (grade 3-4)detailed resultsIMspire-170, 2020 1.77 [0.73; 4.30] 1.77[0.73; 4.30]IMspire-170, 202010%436NAnot evaluable Increase AST AE (grade 3-4)detailed resultsIMspire-170, 2020 3.00 [0.60; 15.03] 3.00[0.60; 15.03]IMspire-170, 202010%436NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsIMspire-170, 2020 1.99 [0.49; 8.06] 1.99[0.49; 8.06]IMspire-170, 202010%436NAnot evaluable Increased Lipase Level AE (grade 3-4)detailed resultsIMspire-170, 2020 2.00 [0.59; 6.74] 2.00[0.59; 6.74]IMspire-170, 202010%436NAnot evaluable Nausea AE (grade 3-4)detailed resultsIMspire-170, 2020 10.02 [0.54; 184.60] 10.02[0.54; 184.60]IMspire-170, 202010%436NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsIMspire-170, 2020 0.98 [0.06; 15.80] 0.98[0.06; 15.80]IMspire-170, 202010%436NAnot evaluable Pruritus AE (grade 3-4)detailed resultsIMspire-170, 2020 0.98 [0.02; 49.71] 0.98[0.02; 49.71]IMspire-170, 202010%436NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsIMspire-170, 2020 6.03 [0.72; 50.50] 6.03[0.72; 50.50]IMspire-170, 202010%436NAnot evaluable Rash AE (grade 3-4)detailed resultsIMspire-170, 2020 7.83 [1.77; 34.66] 7.83[1.77; 34.66]IMspire-170, 202010%436NAnot evaluable Rash maculopapular AE (grade 3-4)detailed resultsIMspire-170, 2020 7.98 [0.42; 151.89] 7.98[0.42; 151.89]IMspire-170, 202010%436NAnot evaluable Sepsis AE (grade 3-4)detailed resultsIMspire-170, 2020 12.08 [0.67; 217.70] 12.08[0.67; 217.70]IMspire-170, 202010%436NAnot evaluable Vomiting AE (grade 3-4)detailed resultsIMspire-170, 2020 2.49 [0.48; 12.97] 2.49[0.48; 12.97]IMspire-170, 202010%436NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-06-14 10:44 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 128 - treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,746,745,856,634,861,416,864,769,980,369,743

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons